Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Memphasys Ltd ( (AU:MEM) ) has shared an update.
Memphasys Limited has appointed Marjan Mikel as a Non-Executive Director, bringing extensive experience in business development and commercialisation across the Medtech, diagnostics, healthcare services, and life sciences sectors. Mikel’s previous roles and familiarity with Memphasys’ strategic vision are expected to aid the company’s global expansion of its Felix™ system and accelerate the commercialisation of the RoXsta™ platform.
More about Memphasys Ltd
Memphasys Limited (ASX: MEM) is a biotechnology company specializing in advanced reproductive biotechnology. The company develops medical devices, diagnostics, and proprietary media for human and animal applications, with flagship technologies like the Felix™ and RoXsta™ Systems aimed at enhancing fertility outcomes worldwide.
Average Trading Volume: 52,211,380
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$7.93M
See more insights into MEM stock on TipRanks’ Stock Analysis page.